Response to Osimertinib in a Patient with Non-Small Cell Lung Cancer and Two Uncommon *EGFR* Mutations
In advanced non-small cell lung cancer (NSCLC), epidermal growth factor receptor (*EGFR*) mutations are one of the most frequent oncogenic drivers. They confer a favorable prognosis and strongly predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs). Over the last decades, several *EGFR* gene...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
THE HEALTHBOOK COMPANY LTD.
2020-03-01
|
| Series: | healthbook TIMES. Oncology Hematology |
| Online Access: | https://doi.org/10.36000/hbT.OH.2020.03.011 |
| Summary: | In advanced non-small cell lung cancer (NSCLC), epidermal growth factor receptor (*EGFR*) mutations are one of the most frequent oncogenic drivers. They confer a favorable prognosis and strongly predict sensitivity to EGFR tyrosine kinase inhibitors (TKIs). Over the last decades, several *EGFR* genetic alterations, common and uncommon mutations, have been described in exons 18−21. Common mutations are exon 19 deletions (most frequently E746-A750) and exon 21 L858R substitution. Uncommon mutations include exon 18 G719X, exon 20 S768l, exon 21 L861Q and many other rare ones. This report describes the case of a 55-year-old woman with a newly diagnosed metastatic lung adenocarcinoma harboring two rare *EGFR* mutations and showing sustained response to osimertinib. |
|---|---|
| ISSN: | 2673-2092 2673-2106 |